Vadimezan

• Description :

  Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.

• CAS Number :

  [117570-53-3]

• Product Name Alternative :

  DMXAA; ASA-404

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H400

• Target :

  IFNAR; Influenza Virus; STING

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Immunology/Inflammation

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer; Infection

• Assay Protocol :

  https://www.medchemexpress.com/DMXAA.html

• Purity :

  99.93

• Solubility :

  DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(O)CC1=CC=CC(C2=O)=C1OC3=C2C=CC(C)=C3C

• Molecular Formula :

  C17H14O4

• Molecular Weight :

  282.29

• Precautions :

  H302, H400

• References & Citations :

  [1]Downey CM, et al. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014 Jun 18;9 (6) :e99988.|[2]Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89 (3) :351-7.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3